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Aims A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly)
has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) lev-
els. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for suscepti-
bility to muscle-related symptoms. We examined the association of this variant with statin intolerance ascertained
from electronic medical records in the GoDARTS study.
...................................................................................................................................................................................................
Methods
and results
In the GoDARTS cohort, the LILRB5 Asp247 variant was associated with statin intolerance (SI) phenotypes; one
defined as having raised CK and being non-adherent to therapy [odds ratio (OR) 1.81; 95% confidence interval
(CI): 1.34–2.45] and the other as being intolerant to the lowest approved dose of a statin before being switched to
two or more other statins (OR 1.36; 95% CI: 1.07–1.73). Those homozygous for Asp247 had increased odds of
developing both definitions of intolerance. Importantly the second definition did not rely on CK elevations. These
results were replicated in adjudicated cases of statin-induced myopathy in the PREDICTION-ADR consortium
(OR1.48; 95% CI: 1.05–2.10) and for the development of myalgia in the JUPITER randomized clinical trial of rosu-
vastatin (OR1.35, 95% CI: 1.10–1.68). A meta-analysis across the studies showed a consistent association between
Asp247Gly and outcomes associated with SI (OR1.34; 95% CI: 1.16–1.54).
...................................................................................................................................................................................................
Conclusion This study presents a novel immunogenetic factor associated with statin intolerance, an important risk factor for
cardiovascular outcomes. The results suggest that true statin-induced myalgia and non-specific myalgia are distinct,
with a potential role for the immune system in their development. We identify a genetic group that is more likely
to be intolerant to their statins.
                                                                                                                                                                                                                   
Keywords Statins • Pharmacogenetics • Immunogenetics • Precision medicine • Adverse drug reactions • Myalgia
* Corresponding author. Tel: þ44 01382 383155, Fax: þ44 01382 383598, Email: c.n.a.palmer@dundee.ac.uk
VC The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
European Heart Journal (2017) 0, 1–8 CLINICAL RESEARCH
doi:10.1093/eurheartj/ehx467 Prevention and epidemiology
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Introduction
Statins are first choice lipid-modifying medications for prevention and
management of cardiovascular diseases (CVD).1,2 The UK is one of
the largest users of statins worldwide,3 and with revised NICE guide-
lines approximately 12 million UK individuals will be prescribed sta-
tins.4,5 While statins are generally well tolerated, neurological,6 gastro-
intestinal, or muscle-based7,8 adverse drug reactions are reported.
Adverse reactions to statins are likely to manifest as muscle aches
(myalgia) along with elevated creatine phosphokinase (CK).
Adherence to statin treatment is often negatively impacted in
response to adverse reactions.9,10 The inability to adhere to statin
treatment, whether due to statin-induced myalgia or more general
forms of statin intolerance result in poor on-statin outcomes.11
Therefore, examining risk factors predisposing to statin intolerance is
crucial from a public health perspective.
A genome-wide association study (GWAS) by Dube´ et al.,12
reported a missense variant Asp247Gly in the leukocyte
immunoglobulin-like receptor subfamily B member 5 gene, LILRB5 on
chromosome 19, base position 54759361 (Human Genome Build
GRCh37), was associated with circulating serum CK levels. The mean
CK levels of Asp247 homozygotes (T/T) were significantly higher. This
association was found to be independent of statin use, however there
is no known biological mechanism for the variant in determining CK
levels. A GWAS by Kristjansson et al.13 of over 60 000 Icelanders repli-
cated the association of the variant and CK levels. The same study also
reported the association of the variant with serum lactate dehydrogen-
ase (LDH) levels in a population of over 90 000 Icelanders.13 The
LILRB5 variant showed the same direction of effect, i.e. Asp247 homo-
zygotes had higher LDH and CK levels. LDH is often used in conjunc-
tion with CK as a marker of tissue damage. The findings suggest the
variant might impart a statin independent susceptibility to muscle-
based events. This makes LILRB5 a potential marker for susceptibility to
the commonly noted muscle-based symptoms attributed to statin
intolerance.
These discoveries warrant an investigation into the role of the
LILRB5 variant in statin intolerance. Population-based studies use sur-
rogate markers of intolerance, such as elevations in CK, trends in sta-
tin treatment, dose reductions, switching or the discontinuation of
therapy. Therefore, a priori, we considered two definitions of statin
intolerance, one dependent on and one independent of elevated CK
levels. We hypothesize that carriers of variant associated with higher
muscle enzyme levels (CK and LDH) will also be predisposed to
forms of statin intolerance independent of CK levels.
The principal cohort used was the Genetics of Diabetes Audit and
Research, Tayside Scotland (GoDARTS). GoDARTS has been previ-
ously used to establish pharmacogenetic associations of genes such
as the hepatic influx transporter SLCO1B1 and statin intolerance.14 At
present, GoDARTS contains 11 912 statin users and provides
approximately 98 000 person-years of statin exposure, providing an
ideal cohort to examine the association of this genetic variant with
statin intolerance. Replication was examined in the Clinical Practice
Research Datalink (CPRD) STAGE study15 and clinically adjudicated
cases of statin-induced myopathy (SIM) in the European
PREDICTION-ADR consortium study.9 The interaction of this effect
with statin use was then studied among participants who developed
myalgia in the JUPITER (Justification for the Use of Statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin) random-
ized clinical trial (RCT) where individuals were allocated rosuvastatin
or placebo to assess the relative reduction in vascular events.16,17
Methods
GoDARTS cohort
Study population
Tayside Medical Ethics Committee approved the GoDARTS study and
informed consent was obtained for all participants. The dataset contains
complete electronic medical records (EMR), prescription information
and laboratory results from 18 306 Scottish Caucasian individuals.
Prescribing data were available from 1 January 1990 to 31 July 2013. In all,
10 149 study participants had type 2 diabetes (T2D) at recruitment and
the remainder (8157) were recruited as non-diabetic controls. We per-
formed a case-control study for statin intolerance in this population. We
found 11 947 statin users from GoDARTS who had at least two prescrip-
tions of statins. The prescription patterns indicating intolerance used in
this study are similar to those used by Donnelly et al.14 to establish the
association between statin intolerance and SLCO1B1 genotypes in the
GoDARTS study. For features used to define statin intolerance and toler-
ance, see Supplementary Material online, Methods S1.
Statin intolerance in GoDARTS
General statin intolerance
Cases of general statin intolerance (GSI) were defined as users with CK
raised above the ULN (Upper Limit of Normal), after start of statin ther-
apy, who either switched statin therapies two or more times (not includ-
ing systemic shifts to atorvastatin after patent expiration in the UK) or
discontinued therapy (n= 588). Controls (statin tolerant individuals—
ST1) had over 90% coverage with statin prescriptions, for a minimum of
5 years, at a minimum average daily dose of 40 mg of simvastatin (or
equivalent dose of another statin), had consistently normal CKs while on
statins, had never switched their statin therapy (except the systematic
switch to atorvastatin) and had not discontinued therapy (n= 356).
Lowest approved daily starting dose statin intolerance
Since the LILRB5 Asp247Gly variant was known to be associated with CK
levels, a phenotype independent of CK elevations was created in order to
determine if the association of the variant with statin intolerance was con-
founded by the variant‘s association with CK levels. The European
Society of Cardiology and European Atherosclerosis Society joint recom-
mendations on the management of dyslipidaemias suggest cessation of
statin treatment if the user presents with normal CK, but persistent
symptoms of intolerance.18 This intolerance definition was derived from
the GAUSS-2 trial, the consensus definition based on recommendations
by Banach et al. and recommendations of the National Lipid Association
(NLA) in 2014.19–22
Cases of low dose intolerance (LDI) had used two or more different
statins, and at least one statin that was discontinued would have to be at
the lowest approved daily starting dose (NLA, 2014) before discontinua-
tion, irrespective of their CK levels (n= 591). Controls (statin tolerant
individuals—ST2) met all the criteria of the previous statin tolerant (ST1)
group, except the definition was independent of the CK elevation criteria
(n= 443). A higher proportion of controls had CK levels in the normal
range, specifically, 354 of the 443 (80%) controls compared to 335 of 591
(57%) cases. Therefore, association tests for this phenotype were
adjusted for (log-transformed) CK levels, in addition to other covariates.
For genotyping methods, see Supplementary material online,Methods S1.
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Validation of statin intolerance phenotypes in GoDARTS
These phenotypic definitions of statin intolerance were validated against
known SLCO1B1 genotype risk score14 and the outcome of major
adverse cardiovascular event (see Supplementary material online,
Methods S2). They were significantly associated with both.
Replication studies
CPRD-STAGE study: statin-induced myopathy
Replication was sought from the CPRD-STAGE study.15 Data were avail-
able for 129 cases of SIM and 2501 population controls from the
Wellcome Trust Case Control Consortium (WTCCC1).15 Cases of sta-
tin myopathy were identified using CPRD and tertiary muscle clinics and
conformed to SIM classification standards.9 Analysis presented is unad-
justed for covariates due lack of available data for the WTCCC popula-
tion controls. For additional cohort information, see Supplementary
material online, Methods S3.
PREDICTION-ADR: statin-induced myopathy
Cases and controls for SIM were contributed by the consortium‘s study
centres in Uppsala (Sweden), Dundee and Liverpool (UK). Cases met crite-
ria for classification of SIM.9 Identification of SIM from population cohorts:
GoDARTS, Genetics of Scottish Health Registry (GoSHARE)23 and CPRD
using EMRs was based on on-statin CK levels raised >_4 times ULN.
Subsequently, clinical adjudication was undertaken by physicians and spe-
cialists. Factors considered were resolution of CK after de-challenge, post-
event prescribing changes (e.g. switching or total discontinuation), medical
history of kidney disease, trauma, falls, myocardial infarction, thyroid disease
and tests for HMGCR (3-Hydroxy-3-Methylglutaryl-CoA Reductase) anti-
bodies, muscle biopsy and physical activity, if available. Cases were also
identified from CVD clinics, general practitioners (GP) practices, and
muscle disease clinics where adjudication was performed directly by physi-
cians. Swedish cases were selected from Swedegene Biobank, which
recruits patients reported to the adverse drug reaction registry at Medical
Products Agency, Uppsala. Statin tolerant controls were on therapy for a
minimum of 1 year with no recorded adverse events. Analysis was per-
formed on 229 cases of SIM and 432 adjudicated controls of Caucasian eth-
nicity. Whole-exome sequencing was undertaken in laboratories in
Liverpool, Dundee and Uppsala. For details of sequencing methods, see
Supplementary material online, Methods S4. There were no sample over-
laps from GoDARTS in the discovery and replication cohorts.
JUPITER trial: myalgia
The replication in JUPITER focused on 8749 study participants of verified
European ancestry with available genetic data among whom 4381 were
randomized to receive statin treatment and 4368 were randomized to pla-
cebo. The population demographics of the genotyped sub-population of
the JUPITER trial has been previously described.16 The median follow-up
period in the trial was 1.9 years, during which traits such as CK, therapy
compliance, and myalgia were recorded.17 Myalgia was ascertained by
physicians blinded to trial-allocation arm24 and 837 participants in the
study sample were recorded as developing myalgia. Due to possible asso-
ciation between CK measures and diagnosis of myalgia, log-transformed
final CK levels were included in analyses as a potential confounder. For
genotyping methods, see Supplementary material online, Methods S1.
Statistical analyses
All statistical analyses on GoDARTS, CPRD-STAGE, and PREDICTION-
ADR data were performed in SAS 9.3 (SAS Institute, Cary, NC, USA).
Statistical analyses in JUPITER were performed using R.25 Binary logistic
regression was used to test the association between the variant and each
phenotype of intolerance. Covariates associated with intolerance such as
gender, age, co-medication usage, type of statin, dose of statin, and CK
levels were added to models where appropriate and available. A back-
wards step-wise approach was used to eliminate covariates that were not
significant predictors in adjusted models. Finally, a fixed-effects meta-anal-
ysis on results from the discovery and replication cohorts was performed.
Only one phenotype from GoDARTS could be selected since the two
groups contained overlapping individuals. LDI phenotype was selected as
the phenotype definition did not include the CK levels and the model was
adjusted for CK measures. The analysis was performed using the metafor
package in R26 and results are presented in a Forest plot (Figure 1).
The minor allele frequency in GoDARTS, CPRD, PREDICTION-ADR,
and JUPITER study populations were 0.37, 0.39, 0.37, and 0.40, respec-
tively. The effect of the LILRB5 variant was considered dominant based on
large-scale analyses with serum CK in GoDARTS (see Supplementary
material online, Results S1). Therefore all association tests compared those
homozygous for Asp247 (T/T) with carriers of 247GlyX (T/C or C/C).
Results
Baseline characteristics of general statin
intolerance and low dose intolerance
Covariates associated with statin use or with the development of
adverse drug reactions (ADR) were tested. Specifically, mean age at
start and end of statin therapy, sex, diagnosis of T2D, first and last sta-
tin used, starting and ending doses, use of interacting co-medications,
statin use for the secondary prevention of CVD, CK levels, and LDL
levels prior to statin use. The Comparison of GSI with statin tolerance
(ST1) and of LDI with statin tolerance (ST2) is presented (Table 1).
Covariates associated with GSI included younger age at start and
longer duration of therapy, female gender, lower incidence of simvas-
tatin use at the start and end of therapy, lower starting and ending
dose, the use of interacting co-medications and, by phenotype defini-
tion, CK levels at time of diagnosis.
Covariates associated with LDI included longer duration of statin
therapy, lower frequency of simvastatin use at the start and end of
Figure 1 Forest plot representing meta-analysis of the associa-
tion between LILRB5 Asp247Gly and outcomes observed across
GoDARTS, CPRD-STAGE, PREDICTION-ADR, and JUPITER stud-
ies. Study sample size is in parentheses. LDI, low-dose intolerance;
SIM, statin-induced myopathy.
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..therapy, lower starting and ending dose, the use of interacting co-
medications and CK levels. A concern with a phenotype that is dose
dependent is that differences might arise from LDL cholesterol
reduction required between tolerant and intolerant individuals, how-
ever LDL levels prior to statin therapy were not significantly different
across the groups.
Association between statin intolerance
and the LILRB5 Asp247Gly variant in
GODARTS
The variant effect was observed in both unadjusted and adjusted
models for both phenotypes (Table 2). Individuals homozygous for
Asp247 had 1.96 [(95% confidence interval (CI): 1.25–3.07] times the
odds of having GSI compared with carriers of the 247Gly variant, in a
model adjusted for first statin on therapy, dose, age, sex, and concur-
rent use of interacting medications (Table 2). For LDI, individuals
homozygous for LILRB5 Asp247 genotype had 1.43 (95% CI: 1.10–
1.86) times the odds of being intolerant compared to carriers of the
247Gly variant, in a model adjusted for the first and last statin on
therapy, CK levels and concurrent use of interacting medications
(Table 2).
Results of replication studies
Replication of the genotypic effect was noted in two out of three
studies of statin-related adverse outcomes. In the CPRD-STAGE
study, the association was found to be non-significant [odds ratio
............................................... .................................................
....................................................................................................................................................................................................................
Table 1 Contrasting general statin intolerance with raised CK and statin tolerance (ST1) and low dose intolerance
with statin tolerance (ST2)
Variables GSI P-value LDI P-value
Cases
(n5 588)
Controls
(n5 356)
Cases
(n5 591)
Controls
(n5 443)
Mean age start therapy (SD) 60 (10) 62 (10) 0.005 60 (10) 60 (10) 0.9
Years on statin therapy (SD) 10.4 (5) 9.3 (3) <0.0001 10 (5) 9.5 (3) 0.007
Sex (% females) 50 43 0.007 48 46 0.16
Type 2 diabetics (%) 78 79 0.68 92 90 0.33
First statin as simvastatin (%) 64 71 <0.0001 59 65 <0.0001
Last statin as simvastatin (%) 31 41 <0.0001 31 36 <0.0001
Starting dose as ‘low’ (<20 mg/day) (%) 85 53 <0.0001 94 37 <0.0001
Ending dose as ‘high’ (>_80 mg/day) (%) 22 36 <0.0001 23 50 <0.0001
Interacting co-medications (yes %) 52 44 0.0025 51% 42% <0.0001
Statin use for secondary prevention of CVD (%) 27 23 0.18 28% 25% 0.3
CK levels (IU/L)a
Median 200 76 <0.0001 98 85 <0.0001
Mean (minimum, maximum) 306 (120, 12, 700) 81 (17, 179) 170 (13, 12 735) 107 (19, 1369)
LDL levels (mmol/L)a
Median 3.5 3.2 0.07 3.2 3.1 0.38
Mean (minimum, maximum) (3.5) (1.1, 5.5) 3.2 (0.4, 8.7) 3.1 (1.1, 6.4) 3.2 (0.5, 8.7)
aIndicates associations were tested using log 10 transformed values.
SD, standard deviation; GSI, general statin intolerance; LDI, Low dose intolerance.
.......................................................................................................................................................................
.......................................................................................................................................................................
............................................................................... ...............................................................................
....................................................................................................................................................................................................................
Table 2 Association of phenotypes of statin intolerance with LILRB5 Asp247Gly
Statin intolerance
phenotype description
LILRB5
Asp247Gly (T/C)
Unadjusted model Adjusted model
Asp247Asp vs. Gly247X: OR (95% CI) P-value Asp247Asp vs. Gly247X: OR (95% CI) P-value
GSI 1.62 (1.24, 2.12) 4 10-4 1.96 (1.25–3.07) 3 10-3
LDI 1.36 (1.07, 1.73) 0.013 1.43 (1.10–1.86) 7 10-3
Odds of intolerance for those homozygous for the ancestral allele (Asp247: T/T) are being contrasted to carriers of the minor allele (Gly247X: T/C or C/C) first in main effects
or unadjusted models and later in models adjusted for significant covariates. For GSI, the covariates were first statin on therapy, dose of the statin, age, sex and concurrent use
of interacting medications. For LDI, the covariates were the first and last statin while on therapy, CK levels and concurrent use of interacting medications.
GSI, general statin intolerance; LDI, Low dose intolerance; CK, creatine phosphokinase; OR, odds ratio; CI, confidence interval.
4 M.K. Siddiqui et al.
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(OR) 1.03, 95% CI: 0.72–1.49] in a main effects model. However, in
the PREDICTION-ADR cohort of SIM, individuals homozygous for
LILRB5 Asp247 had higher odds of developing SIM (OR 1.48, 95% CI:
1.02–2.10) compared to those carrying the 247Gly variant (Table 3).
Cases and controls were matched for sex, type of statin at time of
event during recruitment. The analysis was adjusted for study centre.
In the JUPITER trial, LILRB5 Asp247Gly had a statistically significant
effect on development of myalgia. In a model adjusted for final CK
levels and treatment allocation arm, individuals homozygous for
Asp247 had 1.35 (95% CI: 1.07–1.71) times the odds of developing
myalgia compared to 247Gly variant carriers (Table 4). Interestingly,
interaction between genotype and statin use was significant (P-value
0.04). An analysis of effect stratified by genotype (Table 5), showed
that a statin-specific myalgia effect is only seen among 247Gly variant
carriers. Therefore, while Asp247 homozygotes have an overall
higher risk of myalgia, statin-induced myalgia is only observed in
247Gly variant carriers. Similar results are observed in survival analy-
sis (see Supplementary material online, Results S2).
Meta-analysis of results
A meta-analysis of the observed effects across GoDARTS, CPRD-
STAGE, PREDICTION-ADR and JUPITER revealed that overall,
Asp247 homozygotes have 1.34 (95% CI: 1.16–1.54) times the odds
of having outcomes associated with statin intolerance compared with
carriers of the 247Gly variant (P-value 7 10-5) (Figure 1).
Discussion
We report that the LILRB5 Asp247 homozygous genotype is associ-
ated with increased risk of outcomes associated with statin intoler-
ance across observational, clinically adjudicated and clinical trial
datasets. We observe a consistent relationship of increased risk of
statin intolerance and the LILRB5 Asp247 genotype using two defini-
tions of intolerance in the GoDARTS population. There was congru-
ent association with adjudicated cases and controls of SIM in the
PREDICTION-ADR study and with myalgia in the JUPITER trial, but
no significant association in the CPRD-STAGE study.
A possible mechanism for the role of LILRB5 in muscle pathology is
suggested by a recent study by Kuswanto et al.27 who highlight a role
for the immune system in the repair and regeneration of skeletal
muscles. They report that the presence and rapid accumulation of T
regulatory (Treg) cells is crucial in the repair of damaged skeletal
muscles. It is also reported that statins increase both the number and
suppressive function of CD4þ Foxp3þ Treg cells28; Foxp3 is a tran-
scription factor that is the master regulator of Treg immune-
suppressive activity.29 The same study shows sustained increased
expression of Foxp3 with statin use. Therefore, mechanisms that
induce Foxp3 expression and sustain Treg function are of great inter-
est in understanding muscle homeostasis. We examined mRNA
expression data from the GTEx portal and found that the LILRB5
Asp247 variant is associated with FOXP3 mRNA expression in the
spleen (see Supplementary material online, Figure S6).30,31 FOXP3 lies
on the X chromosome, indicating a trans-eQTL effect, with the
LILRB5 variant having an indirect immunomodulatory effect on
FOXP3 expression. These findings underscore a role for immunoge-
netics in understanding muscle damage and repair, with LILRB5
Asp247Gly being the first candidate to be found for common statin
intolerance. An illustration of the potential mechanism is provided in
Supplementary material online, Figure S7.
.................................................................................................
Table 5 Association of rosuvastatin treatment with
myalgia stratified by genotype in the JUPITER trial
Comparison groups Hazards ratio (95% CI) P-value
Asp247 (T/T)
Rosuvastatin vs. placebo 0.87 (0.67–1.12) 0.31
247GlyX (C/T or C/C)
Rosuvastatin vs. placebo 1.23 (1.01–1.50) 0.04
The model was adjusted for log-transformed final CK measures.
CK, creatine phosphokinase; CI, confidence interval.
....................................................................................................................................................................................................................
Table 3 Distribution of LILRB5 Asp247Gly genotypes by clinically adjudicated SIM status
Group Asp247Asp (T/T) Gly247X (T/C or C/C) Total Association
Statin-induced myopathy 96 133 229 Odds ratio = 1.48
Statin tolerant controls 161 271 432 95% CI: 1.05–2.10
Total 257 404 661 P-value 0.025
Cases and controls were selected from PREDICTION-ADR in Dundee, Liverpool and Uppsala. Model was adjusted for study center.
CI, confidence interval.
.................................................................................................
Table 4 Odds ratios of developing myalgia in the
JUPITER trial
Variables b Odds ratio 95%
confidence
interval
P-value
Main effects model
Asp247Asp vs.
247GlyX Gly247X
0.16 1.17 (1.02–1.35) 0.03
Adjusted model
Asp247Asp vs. 247GlyX 0.30 1.35 (1.07–1.71) 0.01
Rosuvastatin vs. placebo -0.13 0.88 (0.68–1.13) 0.34
Final CK measure
(log transformed)
0.19 1.21 (0.87–1.69) 0.26
Asp247Gly*rosuvastatin -0.34 0.71 (0.51–0.99) 0.04
The adjusted model accounts for treatment allocation arm and final CK
measures.
CK, creatine phosphokinase.
LILRB5 variant, statin intolerance, and myalgia 5
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Previously proposed mechanisms for SIM include an association
between statins and reduced mitochondrial function, attenuated
energy production, and altered muscle protein degradation contribu-
ting to muscle symptoms.32,33 Studies have shown evidence of struc-
tural perturbations in skeletal muscle cells associated with statin
use.34,35 However, other studies failed to observe such abnormalities.36
There are other known immune-mediated forms of statin-related
myopathies such as idiopathic inflammatory myositis or immune-
mediated necrotizing myopathy, however these are very rarely
observed.37,38 Overall, however, there remains a lack of clarity about
the underlying pathophysiology of statin intolerance.18
While the current variant results in an amino acid substitution, it is
not clear that the phenotype results from this protein change. This is
especially true as this variant is also associated with LILRB5 expression
in certain tissues in the GTEx portal database (see Supplementary
material online, Figure S8).30,31 We used GTEx to identify the stron-
gest cis-eQTLs for LILRB5 expression, and found SNPs rs1408812
and rs3852892 showed much stronger effects in skeletal muscles and
whole blood, respectively (see Supplementary material online, Figures
S9 and S10). However, these polymorphisms have no known associa-
tions with CK, LDH or statin intolerance and were not in linkage with
the Asp247Gly variant. This demonstrates that the observed pheno-
types are not associated with genetically driven variation in LILRB5
expression and therefore the association with the Asp247Gly variant
would appear to be mediated by a functional change in the protein
due to the amino acid substitution. However, this has to be con-
firmed by direct experimentation.
Previous studies have shown that CK levels were associated with
LILRB5 variant12,13 and with all definitions of intolerance, including
diagnoses of myalgia, making it a potential confounder. We have ruled
out any artefactual associations by including CK measures as a covari-
ate in analyses, where appropriate. Since the GSI phenotype in
GoDARTS and diagnoses of myopathy in CPRD-STAGE and
PREDICTION-ADR were entirely dependent on elevated CK, this
adjustment was not possible. Additionally, the findings of this study
could be impacted by confounders that were unmeasured in the
cohorts used. Indeed, the non-significant finding in CPRD-STAGE
might be due to the use of population controls with no available clini-
cal or demographic information, limiting inclusion of important cova-
riates in the analysis.
Another source of bias in non-randomized studies could be drug
interactions that are known to increase risk of SIM.39 Inhibition of
cytochrome P450 (CYP) 3A4 can increase exposure to simvastatin
and atorvastatin several fold. On the other hand, inhibition of hepatic
influx transporter OATP1B1 by drugs such as gemfibrozil can
increase plasma concentrations of all statins.40 Due to the increased
risk of muscle toxicity with combination therapy,41 fibrates are not
generally recommended for concurrent use with statins for primary
lipid control,42 but are co-prescribed to patients with T2D to control
triglyceride levels. Since GoDARTS is primarily a population of T2
Diabetics, fibrates are widely prescribed in the study population. We
observe comedications, especially fibrates consistently increased the
risk of statin intolerance. However, in adjusted models, the associa-
tion of the LILRB5 Asp247Gly variant was independent of the effect
of these co-medications. Additionally, the effect is observed in the
RCT setting, which confirms that the results from our observational
data are not biased.
This finding, in addition to other previously reported genetic asso-
ciations can facilitate the development of gene risk scores for the pre-
vention of adverse outcomes to statin therapy. Preliminary analyses
in GoDARTS reveal a significant interaction between the known
SLCO1B1 polymorphisms and LILRB5 Asp247Gly (see Supplementary
material online, Results S4). This would suggest that we are making
progress in dissecting 3the complex genetic architecture of statin
intolerance, but future studies would be required to examine the
corresponding pharmacokinetics of specific statins such as rosuvasta-
tin that are not affected by SLCO1B1.
The JUPITER trial allowed us to examine the association of the
LILRB5 Asp247Gly variant in the presence and absence of statins,
revealing that homozygosity of Asp247 is associated with increased
odds of myalgia regardless of statin allocation. This supports the con-
cept that LILRB5 Asp247 homozygous genotype modulates CK and
LDH levels through statin-independent muscle damage. The associa-
tion of 247Gly carriers with the development of myalgia in JUPITER is
suggestive of a more complex biological gene–drug interaction. The
observation that 247Gly carriers showed statin-specific myalgia, sug-
gests a subpopulation of individuals who are inherently protected
from myalgia, are susceptible to true ‘statin-induced’ myalgia. In
observational data such as GoDARTS it is impossible to determine if
intolerance to statins is occurring due to statin-specific or non-
specific side effects. However, occurrence of intolerance is associated
with increased risk of adverse CV outcomes (see Supplementary
material online, Methods S2). We believe a recruit-by-genotype trial
would be the ideal platform to examine the statin-dependency by
LILRB5 Asp247Gly genotypes, and to further explore the underlying
immune mechanisms.
Clinical trials have consistently found no evidence of statin-specific
myalgia, just as there is no difference in incidence of myalgia between
placebo and rosuvastatin arms of the JUPITER trial.17,24 The lack of
association of statins with muscle pain in RCTs has led to a debate
regarding the existence of statin-related muscle symptoms. Indeed
the difficulty of ascribing causality in statin related muscle symptoms
is highlighted by the Goal Achievement after Utilizing an anti-PCSK9
Antibody in Statin-Intolerant Subjects -3 (GAUSS-3) trial.43 Data
from this trial were the first systematic evaluation of statin-specific
myalgia with rechallenge and provided an estimate of 43% of individu-
als having statin-specific myalgia, and also demonstrated that 37% of
intolerant individuals have statin-independent or non-specific myalgia.
The LILRB5 Asp247Gly genotype presents a unique opportunity to
probe the immune mechanisms behind the phenomena of muscle
pain specific to statins compared to ‘constitutive’ muscle pain that
appears in LILRB5 Asp247 homozygotes.
Supplementary material
Supplementary material is available at European Heart Journal online.
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